Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Initial Efficacy of LNF1901 in Advanced Malignant Tumors

NCT06226363 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.

NCT NCT06226363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06226363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Initial Efficacy of LNF1901 in Advanced Malignant Tumors
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD
Phase
Phase 1
Overall status
Not yet recruiting
Start date
February 1, 2024
Completion date
February 1, 2027
Enrollment
82 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant tumors